ATE454165T1 - Methoden um rotavirusvarianten zu trennen und lebender attenuierter rotavirus impfstoff - Google Patents

Methoden um rotavirusvarianten zu trennen und lebender attenuierter rotavirus impfstoff

Info

Publication number
ATE454165T1
ATE454165T1 AT06075774T AT06075774T ATE454165T1 AT E454165 T1 ATE454165 T1 AT E454165T1 AT 06075774 T AT06075774 T AT 06075774T AT 06075774 T AT06075774 T AT 06075774T AT E454165 T1 ATE454165 T1 AT E454165T1
Authority
AT
Austria
Prior art keywords
rotavirus
attenuate
live
separate
methods
Prior art date
Application number
AT06075774T
Other languages
English (en)
Inventor
Brigitte Desiree A Colau
Francoise Denamur
Isabelle Knott
Annick Poliszczak
Georges Thiry
Velde Vincent Vande
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE454165T1 publication Critical patent/ATE454165T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT06075774T 1999-08-17 2000-08-15 Methoden um rotavirusvarianten zu trennen und lebender attenuierter rotavirus impfstoff ATE454165T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9919468.0A GB9919468D0 (en) 1999-08-17 1999-08-17 Vaccine

Publications (1)

Publication Number Publication Date
ATE454165T1 true ATE454165T1 (de) 2010-01-15

Family

ID=10859327

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06075774T ATE454165T1 (de) 1999-08-17 2000-08-15 Methoden um rotavirusvarianten zu trennen und lebender attenuierter rotavirus impfstoff

Country Status (12)

Country Link
EP (1) EP1676586B1 (de)
CN (1) CN101302500A (de)
AT (1) ATE454165T1 (de)
CY (1) CY1109976T1 (de)
DE (1) DE60043676D1 (de)
DK (1) DK1676586T3 (de)
EC (1) ECSP003623A (de)
ES (1) ES2339043T3 (de)
GB (1) GB9919468D0 (de)
PT (1) PT1676586E (de)
SI (1) SI1676586T1 (de)
ZA (1) ZA200201266B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2888355B1 (de) * 2012-08-27 2020-06-17 Murdoch Childrens Research Institute Modifizierte humane rotaviren und verwendungen dafür
HRP20211838T1 (hr) * 2015-05-21 2022-03-04 Xiamen University Krnji protein vp4 rotavirusa i njegova primjena
JP2019502685A (ja) * 2015-12-18 2019-01-31 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 熱安定性ロタウイルスワクチン製剤およびその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341763A (en) * 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4571385A (en) * 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
WO1992008786A1 (en) 1990-11-16 1992-05-29 James N. Gamble Institute Of Medical Research Human rotaviruses, vaccines and methods
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
EP0988053A1 (de) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Gereinigte saponinen als orale adjuvantien

Also Published As

Publication number Publication date
DE60043676D1 (de) 2010-02-25
CN101302500A (zh) 2008-11-12
EP1676586A1 (de) 2006-07-05
ECSP003623A (es) 2002-02-25
GB9919468D0 (en) 1999-10-20
SI1676586T1 (sl) 2010-04-30
PT1676586E (pt) 2010-04-07
DK1676586T3 (da) 2010-05-10
ZA200201266B (en) 2003-01-29
CY1109976T1 (el) 2014-09-10
EP1676586B1 (de) 2010-01-06
ES2339043T3 (es) 2010-05-14

Similar Documents

Publication Publication Date Title
AP1768A (en) Vaccine
ES2153223T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
DE60012711D1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
CY1113419T1 (el) Εμβολιο συνδυασμου που εχει μειωμενες ποσοτητες αντιγονου ιου πολιομυελιτιδας
FR11C0027I2 (fr) Virus de l'influenza recombinants pour vaccins et traitement genetique
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
BR9808933A (pt) Composição sob forma de microcápsulas ou de implantes, processo de preparação de uma substância hidrossolúvel, substância ativa, acetato de triptorelina, acetato de lanreotìdeo, ou acetato de octreotìdeo, e rna de filamento duplo
NO976060L (no) Vaksiner mot hepatitt C
DK0588578T3 (da) Immunogener
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
DK0404625T3 (da) Oligonukleotidsekvenser til amplifikation af genomer af retrovirus af HIV-2 og SIV-typen samt deres anvendelser til in vitro-diagnose af infektioner forårsaget af disse virus
DE60043676D1 (de) Methoden um Rotavirusvarianten zu Trennen und lebender attenuierter Rotavirus Impfstoff
AR019250A1 (es) Formas atenuadas del virus de la diarrea viral bovina, molecula de acido nucleico, vector, uso, metodo para modificar el genoma viral de tipo salvaje, genoma modificado, vacuna, metodo para atenuar un virus bvd de tipo salvaje
AR021948A1 (es) Metodo para preparar una vacuna inactivada, adyuvada con una emulsion a/a y kit de partes
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
ATE334697T1 (de) Boviner atmungs- und darmcoronavirus als impfstoff
ES2122973T3 (es) Vacuna de recombinante de rotavirus.
DK76688A (da) Vaccine indeholdende f-proteinet fra aids-virus
EP1155119A4 (de) Virusimpfstoff charakterisiert durch bhv-1-gendeletion
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
RU2006118106A (ru) Вектор химерного аденовируса типа 5/типа 35
PT1149901E (pt) Mutantes de pestivirus e vacinas contendo os mesmos
KR950031109A (ko) 돼지 유행성 설사병(red)과 전염성 위장염(tge)바이러스 혼합사독 유성백신의 제조방법
ES2105984B1 (es) Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
Bjorvatn et al. Vaccinations in Health Strategies of Developing Countries: The Role of Biotechnology and Social Sciences

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1676586

Country of ref document: EP